Solid Biosciences Inc (NAS:SLDB)
$ 8.52 -0.6 (-6.58%) Market Cap: 326.99 Mil Enterprise Value: 169.77 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 40/100

Solid Biosciences Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript

Apr 24, 2023 / 06:00PM GMT
Release Date Price: $4.81 (-1.03%)
Geulah Livshits
Chardan Capital - Analyst

Good afternoon. It's now my pleasure to introduce Kevin Tan, CFO; Paul Herzich, CTO; and Brian Collins, SVP at Solid. Thank you all for joining us today. The format for this session, roughly a 25 minutes fireside chat. (Operator Instructions) And to start off, perhaps you could give us an overview of Solid' CMC capabilities and how they fit into the company's overall strategy and the overall approach going forward?

Kevin Tan
Solid Biosciences, Inc. - CFO

Absolutely. Thank you so much for having us, and we're so please be participating in the Chardan conference and the manufacturing summit.

I think I'll start off first by just reiterating that there may be forward-looking statements made and we may need to disclaim any obligation update that in the future, even if they do change.

I think it's important [suite] to orient everyone around Solid as a new company. In December 2, 2022, we completed our merger with Avanti Biosciences and combined both companies' pipelines. People here might remember Solid

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot